NewsCBDEurope’s Glaring National Differences Over CBD

Europe’s Glaring National Differences Over CBD

-

OVER three quarters of Brits are familiar with CBD, whilst in France, just over one-third aware of it.

The French are also the most sceptical of CBD whilst their Swiss neighbours are the most engaged, European research has revealed.

The findings from New Frontier Data found French respondents are least likely to agree that CBD had valid medical uses – at 46% – nine points less than the rest of Europe.

Whilst they are also the most likely to believe that CBD should only be available with a doctor’s recommendation, at 49%, compared to 36% on the rest of the continent.

Meanwhile, in Switzerland and Austria more than half – 53% – are positive about CBD, compared to 42% of Europeans overall.

The October 2019 European CBD Survey polled 3,100 respondents from the continent about their attitudes and CBD use.

It found that most consumers are using CBD to treat, pain, at 40%, for relaxation, at 34%, and to reduce stress and anxiety levels at 31% and 26% respectively.

In relation to CBD usage the French were once again at the bottom with 7% compared to 16% of all Europeans.

There is also a marked difference in familiarity with cannabidiol – or CBD – in France at 36% compared to 78% in the United Kingdom and Ireland. 

However, this French scepticism towards CBD, and all things cannabis, is currently under attack from two sides.

Earlier this year the Government approved the country’s first medical cannabis trial, and the French Parliament looks set to ease restrictions on the CBD wellness market.


Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Plans Unveiled For First National Health Service-Backed Medical Cannabis Clinical Trial

AFTER launching a patient registry earlier this year further signs the UK’s National Health Service is warming to cannabis...

Reakiro – Europe’s Leading CBD And Hemp Brand – Delivers The Complete B2B & B2C Package

IN a time when CBD products are becoming unavoidable in the health, wellness and fitness industries, it is more...

Is Luxembourg’s Quest To Introduce An Adult-Use Cannabis Programme Going Up In Smoke?

CONCERNS over Luxembourg’s intent to become the first European country to legalise adult-use cannabis have emerged. In an interview on...

Cannabis Is Now A Compelling Opportunity For The Main Tobacco Companies

International cannabis expert, Barbara Pastori, of Prohibition Partners shares her thoughts on why cannabis is a compelling opportunity for...

Oxford Cannabinoid Technologies Holdings Sign Exclusive Worldwide License Agreement With Canopy Growth

Oxford Cannabinoid Technologies Holdings plc (OCTP), the holding company of Oxford Cannabinoid Technologies Ltd (“OCT”) (together, the “Group”), a...

With Global Cannabis Cultivation Capacity Set To Outstrip Demand One Hundredfold – What Happened To The ‘Green’ Rush?

CANNABIS investors need to be wary when it comes to cultivation, says Oliver Zugel, Founder and CEO FoliuMed Holdings. Where...

Must read

Plans Unveiled For First National Health Service-Backed Medical Cannabis Clinical Trial

AFTER launching a patient registry earlier this year further...

Is Luxembourg’s Quest To Introduce An Adult-Use Cannabis Programme Going Up In Smoke?

CONCERNS over Luxembourg’s intent to become the first European...

You might also likeRELATED
Recommended to you